Shares in Adamis Pharmaceuticals rose 31 percent on Oct. 18 on news that the U.S. Food and Drug Administration approved the company’s naloxone injection Zimhi for the treatment of opioid overdose. This was Adamis’ third attempt to have the drug approved, following two CRLs.
Valneva SE on Oct. 18 said the company’s experimental Covid-19 vaccine demonstrated efficacy “at least as good, if not better” than AstraZeneca’s shot in a late-stage trial comparing the two, with significantly fewer adverse side effects.
Oyster Point Pharma Inc.’s treatment for dry eye disease became the first U.S. approved nasal spray for the chronic condition on Oct. 18, sending the drug developer’s shares higher.
A panel of expert advisers to the U.S. Food and Drug Administration unanimously voted on Oct. 14 to recommend booster shots of Moderna Inc.’s Covid-19 vaccine for Americans aged 65 and older and those at high risk of severe illness or occupational exposure to the virus.
Shares of GlaxoSmithKline climbed in trading on rumors that the consumer health business it intends to spin off into a separate company next year is attracting interest from venture capitalists.
CureVac NV said on Oct. 12 the company will give up on the biotechnology firm’s first-generation Covid-19 vaccine candidate and instead focus on collaborating with GSK to develop improved mRNA vaccine technology.
Supernus Pharmaceuticals Inc. is acquiring Adamas Pharmaceuticals Inc. for about $400 million as the Rockville, Maryland-based company is expanding its portfolio of treatments for Parkinson’s disease and reducing reliance on the drugmaker’s top-selling epilepsy medicine, Trokendi XR.
Two Indian drugmakers requested permission to end their late-stage trials on Merck & Co.’s experimental antiviral drug molnupiravir in moderate Covid-19 patients.
ChemoCentryx Inc. said on Friday the U.S. health agency approved the company’s lead drug for treating a rare, fatal autoimmune disease, sending the biopharmaceutical company’s shares up by more than 70 percent.
The U.S. Food and Drug Administration did not approve Polarean Imaging’s application for a new drug-device combination product, sending the company’s shares tumbling 60 percent.
